<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Abl kinase inhibitor <z:chebi fb="0" ids="31690">imatinib mesylate</z:chebi> is the preferred treatment for <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> (Ph(+)) <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase but is much less effective in <z:mp ids='MP_0005481'>CML</z:mp> <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> or Ph(+) B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we show that Bcr-Abl activated the Src kinases Lyn, Hck and Fgr in B-lymphoid cells </plain></SENT>
<SENT sid="2" pm="."><plain>BCR-ABL1 retrovirus-transduced marrow from mice lacking <z:hpo ids='HP_0000001'>all</z:hpo> three Src kinases efficiently induced <z:mp ids='MP_0005481'>CML</z:mp> but not <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> in recipients </plain></SENT>
<SENT sid="3" pm="."><plain>The kinase inhibitor CGP76030 impaired the proliferation of B-lymphoid cells expressing Bcr-Abl in vitro and prolonged survival of mice with <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> but not <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The combination of CGP76030 and <z:chebi fb="0" ids="45783">imatinib</z:chebi> was superior to <z:chebi fb="0" ids="45783">imatinib</z:chebi> alone in this regard </plain></SENT>
<SENT sid="5" pm="."><plain>The biochemical target of CGP76030 in <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells was Src kinases, not Bcr-Abl </plain></SENT>
<SENT sid="6" pm="."><plain>These results implicate Src family kinases as therapeutic targets in Ph(+) <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and suggest that simultaneous inhibition of Src and Bcr-Abl kinases may benefit individuals with Ph(+) <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>